Le Lézard
Classified in: Health, Science and technology

TGF-beta/Receptor Inhibitors Competitor Analysis 2019 - ResearchAndMarkets.com


The "Competitor Analysis: TGF-beta/Receptor Inhibitors" report has been added to ResearchAndMarkets.com's offering.

This Competitive Intelligence report about TGF-beta/Receptor Inhibitors evaluates the landscape of investigational new molecular entities targeting transforming growth factor-beta (TGF-) and TGF- receptor kinase for the treatment of cancer or fibrosis as of September 2019.

Several cytokines and growth factors are involved in the tight regulation of either antitumor immunity or immunosuppressive tumor-promoting inflammation within the tumor microenvironment (TME), of which transforming growth factor-beta (TGF-) is of particular importance. In mammals, three TGF- isoforms are described (TGF-1, 2, and 3) which are the primary mediators of TGF- cell transduction. All isoforms are synthesised as propeptides that form dimers which require maturation before being able to bind to their receptors. These dimers are composed of the C-terminal TGF- ligand as well as an N-terminal latency-associated propeptide (LAP), with which the complex gets sequester to proteins of the extracellular matrix (ECM).

As preclinical studies implicate the use of TGF- inhibition as a potential therapeutic target, monoclonal antibodies against all three isoforms of TGF-, as well as TGF-R inhibitors, are currently tested in various solid cancers. As the response to anti-PD-1 monotherapy appears to be mainly limited by the number of preexisting cytotoxic T cells, concurrent TGF- inhibition provides a powerful strategy to (a) improve T cell priming within the lymph nodes, (b) enhance cytotoxic destruction of tumor cells, and (c) reduce the appearance of immune-suppressive immune cells.

The report includes a compilation of currently active projects in research and development of TGF-/R inhibitors for the treatment of fibrosis and cancer, respectively. In addition, the report lists company-specific R&D pipelines of TGF- and TGF- receptor kinase inhibitors. Competitor projects are listed in a tabular format providing information on:

Key Topics Covered:

1) Cancer Indications

2) Non-Cancer Indications with TGF- Inhibition

3) Corporate RORgamma Antagonist & Agonist R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/r/o5nefm


These press releases may also interest you

at 05:14
iQIYI, Inc. ("iQIYI" or the "Company"), an innovative market-leading online entertainment service in China, recently won multiple awards at the 15th Chinese American Film Festival and Chinese American TV Festival (the "Festivals") through its...

at 05:05
XILINX DEVELOPER FORUM-- Wind River®, a leader in delivering software for the intelligent edge, today announced a collaboration with Xilinx, Inc. on the development of a comprehensive automated driving platform that integrates Xilinx's Versal...

at 05:00
AMS, Analog Mixed-Signal division of ISSI, announces the IS31SE51111, a capacitive touch sensor solution for a variety of residential and industrial appliances and for IoT touch-sense applications. The IS31SE5111 brings to the market a reliable and...

at 05:00
dynaCERT Inc. (FRA: DMJ) ("dynaCERT" or the "Company") is pleased to announce that it has engaged expert world-renowned data security software company, Cosario Limited of Mississauga (Canada) ("Cosario"), to further ensure global state-of-the-art...

at 05:00
The Global Commission on the Stability of Cyberspace (GCSC) issued today its final report Advancing Cyberstability, as part of a panel held at the 2019 Paris Peace Forum. Stef Blok, Minister of Foreign Affairs of the Netherlands, Jean-Yves Le Drian,...

at 05:00
Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage provider, will demonstrate its newly-launched EonStor CS scale-out NAS at SC 19 (Booth 1695, Nov. 18-21), an international exhibition for high performance computing,...



News published on 21 october 2019 at 10:30 and distributed by: